{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"62.8","upperLimit":"86.1","value":"76.9"},{"groupId":"OG001","lowerLimit":"45.3","upperLimit":"68.0","value":"57.5"},{"groupId":"OG002","lowerLimit":"22.8","upperLimit":"54.9","value":"39.0"},{"groupId":"OG003","lowerLimit":"61.8","upperLimit":"79.7","value":"71.9"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"53"},{"groupId":"OG001","value":"85"},{"groupId":"OG002","value":"41"},{"groupId":"OG003","value":"119"}],"units":"Participants"}],"description":"Probability of being event free (event defined as PD or death due to any cause) at 6 months after the first dose of crizotinib was reported. PD: \\>=20% increase in the sum of the longest diameter of target lesions taking as references the smallest sum longest diameter recorded since the treatment started, unequivocal progression of existing non-target lesions, or the appearance of 1 or more new lesions.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants received Crizotinib 250 mg (2 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet orally twice daily (BID) with or without food for up to 105 cycles (each cycle 28 days).","id":"OG000","title":"RP2D Cohort: ROS1-Positive NSCLC: Crizotinib 250 mg"},{"description":"Participants received Crizotinib 250 mg (2 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet orally twice daily (BID) with or without food for up to 55 cycles (each cycle 28 days).","id":"OG001","title":"RP2D Cohort: MET Exon 14 Alterations NSCLC: Crizotinib 250 mg"},{"description":"Participants received Crizotinib 250 mg (2 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet orally twice daily (BID) with or without food for up to 101 cycles (each cycle 28 days).","id":"OG002","title":"RP2D Cohort: MET Amplification NSCLC: Crizotinib 250 mg"},{"description":"Participants received Crizotinib 250 mg (2 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet twice daily (BID) with or without food for up to 133 cycles (each cycle 28 days).","id":"OG003","title":"RP2D Cohort: ALK-Positive Cohort, NSCLC: Crizotinib 250 mg"}],"paramType":"NUMBER","populationDescription":"SA set included all enrolled participants who received at least one dose of Crizotinib on Cycle 1 Day 1. Here, \"Overall Number of Participants Analyzed\" signifies number of participants evaluable for this outcome measure. Data was planned to be analyzed for reported arms only.","reportingStatus":"POSTED","timeFrame":"From randomization to 6 months","title":"Recommended Phase 2 Dose (RP2D) Cohort: Probability of Being Event Free at Month 6","type":"PRIMARY","unitOfMeasure":"Probability of being event-free"}